TP53 and ovarian carcinoma: Furthermore, combination of AZD1775 and the IRE1α inhibitor MKC8866 show remarkable synergistic effect in multiple TP53‐mutant cell lines and patient‐derived xenograft (PDX) models of ovarian cancer.